Melissa Broske
Payments from drug & device makers
Across 539 payments — averaging $20.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Actelion Pharmaceuticals US, Inc.$1K
- Insmed, Inc.$603
- Boehringer Ingelheim$546
- Bayer$454
- plus $4K from 31 others
What the payments were for
- Food & beverage$11,01298%
- Education$2492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 124 | $2,267 |
| AstraZeneca | 104 | $1,853 |
| Actelion Pharmaceuticals US, Inc. | 51 | $1,385 |
| Insmed, Inc. | 35 | $603 |
| Boehringer Ingelheim | 35 | $546 |
| Bayer | 20 | $454 |
| United Therapeutics Corporation | 19 | $442 |
| Novo Nordisk | 7 | $409 |
| Regeneron Healthcare Solutions, Inc. | 16 | $393 |
| AbbVie | 13 | $353 |
| Mylan Specialty L.p. | 19 | $334 |
| Sanofi | 14 | $306 |
| Mallinckrodt Hospital Products Inc. | 14 | $276 |
| Intuitive Surgical | 2 | $214 |
| Baxter Healthcare | 9 | $197 |
| Shionogi Inc | 7 | $170 |
| Amgen | 6 | $137 |
| Grifols USA, LLC | 6 | $106 |
| Merck | 4 | $105 |
| ANI Pharmaceuticals, Inc. | 5 | $90 |
| Novartis | 4 | $87 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| Advanced Respiratory, Inc | 3 | $73 |
| Melinta Therapeutics, LLC | 3 | $67 |
| Inspire Medical Systems, Inc. | 3 | $56 |
| Teva Pharmaceuticals USA, Inc. | 3 | $42 |
| Harmony Biosciences LLC | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Inogen, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Sandoz | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Electromed, Inc. | 1 | $15 |
| Acacia Pharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$352
- UPTRAVI$334
- OPSUMIT$334
- Da Vinci Surgical System$129
- TYVASO$125
- TRELEGY ELLIPTA$117
- Adempas$109
- AREXVY$109
How this compares
$11,260 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 24 | $302,377 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 335 | $267,584 |
| NucalaMepolizumab | 18 | $90,256 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 97 | $79,431 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 84 | $49,278 |
| Breo ElliptaFluticasone/Vilanterol | 101 | $44,815 |
| Dupixent PenDupilumab | 11 | $43,090 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 34 | $24,619 |
| Spiriva RespimatTiotropium Bromide | 15 | $15,671 |
| SymbicortBudesonide/Formoterol Fumarate | 54 | $14,867 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 271 | $8,936 |
| EliquisApixaban | 11 | $6,380 |
| Wixela InhubFluticasone Propion/Salmeterol | 28 | $5,916 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $3,491 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $2,267 | $454,725550 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,385 | $302,37724 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,853 | $94,298151 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $546 | $40,29049 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Evans
- Morgan GroothandEvans$81K
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.